TS-005604 — This new process of treating fusion-driven pediatric sarcomas centers around the nuclear receptor NR0B1, which has the ability to impede and suppress the response of other nuclear receptors to their natural ligands. Currently there are no targeted therapies approved for fusion-driven pediatric sarcomas, establishing what is likely the first demonstration that disrupting NR0B1 can unmask nuclear receptor–dependent therapeutic responses in a pediatric cancer, offering a novel and potentially safer treatment approach for fusion‑driven sarcomas.

TS-003666 — This advancement in pharmacology targets iron-sulfur cluster biogenesis in mammalian cells. Through the utilization of N’-(1-phenylethylidene)-benzohydrazides, originally developed as LSD1 inhibitors, this discovery highlights their additional inhibitory activity against iron-sulfur cluster biogenesis in mitochondrial environments. With a potent inhibitory effect demonstrated (100s of nM IC50), it holds potential implications as an anticancer, antimicrobial, and/or antiviral agent, independent of any inhibitory action against LSD1. The project is positioned at the proof-of-concept stage, and future work aims to delineate the relationship between iron-sulfur cluster disruption and LSD1 biology, further investigate mitochondrial disruption further, and identify specific targets for potential therapeutic intervention. The disclosed IP is a unique approach to targeting iron-sulfur cluster biogenesis and presents opportunities for diverse commercial applications in the pharmaceutical industry.

TS-003665 — This is a new avenue in genetic research focused on iron-sulfur cluster pathway disruptors. These disruptors, including N’-(1-(2-hydroxyphenyl)-propylidene)-benzohydrazides and N’-(1-(2-hydroxyphenyl)-ethylidene)-benzohydrazides, offer potential applications in altering the iron-sulfur cluster maturation process. Their development signifies a departure from previously explored compounds, particularly those with LSD1 inhibitory activity, thus introducing cleaner compounds for targeted disruption. Ongoing proof of concept testing is slated for completion by year-end. The IP offers a promising path for therapeutic exploration, and the potential applications of these disruptors span various human pathologies, including cancer and infectious diseases.